Patients with cancer are at risk for venous thromboembolism, which can complicate care and increase mortality, but effective approaches are available to prevent or treat the problem. Medscape Hematology-Oncology
Older men with prostate cancer who are on long-term androgen deprivation therapy (ADT) often show physical performance deficits that significantly increase their risk for falls and injury, researchers report. Reuters Health Information
What do clinicians need to know in 2008? Dr. Harold Burstein brings readers up to date about trastuzumab-based regimens, selecting a chemotherapy backbone, and monitoring cardiac function. Medscape Hematology-Oncology
This challenging case presentation addresses the critical treatment decisions warranted for an older male patient with metastatic renal cell carcinoma. Medscape Hematology-Oncology
A meta-analysis has found that platinum-based regimens do not offer significant benefit in survival or overall tumor response, compared with second-line nonplatinum-based regimens. Medscape Medical News
Is progression free survival significantly different when using capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second line therapy? Annals of Oncology
Recent studies have found that specific histologic subgroups of NSCLC respond more favorably to particular therapies. This expert column focuses on the role of histology in selecting NSCLC therapies and improving patient outcomes. Medscape Hematology-Oncology
Sequential vs combination chemotherapy? Bevacizumab? Ixabepilone? Dr. Martine Piccart offers her perspectives on treatment for metastatic breast cancer, with particular focus on quality of life. Medscape Hematology-Oncology
